Blurbs Benchmark Co. Keeps Their Hold Rating on Nephros (NEPH) November 21, 2023 Share FacebookTwitterPinterestWhatsApp Must read Nvidia CEO aiming to set up base in Vietnam, Reuters reports December 10, 2023 Utz Brands to host investor day December 10, 2023 Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term... December 10, 2023 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral... December 10, 2023 Benchmark Co. Keeps Their Hold Rating on Nephros (NEPH) Source link Share FacebookTwitterPinterestWhatsApp Previous articleBitcoin and Ethereum: Ethereum is holding above $2000Next articleSolana and Cardano: Cardano remains below the 0.400 level More articles Universal Music Group (UMGNF) was downgraded to a Hold Rating at Kepler Capital December 10, 2023 Kepler Capital Keeps Their Buy Rating on Genfit (GNFTF) December 10, 2023 Surgery Partners (SGRY): A Solid Buy on Long-Term Growth and Strategic Expansions Despite Near-Term Challenges December 9, 2023 Latest article Nvidia CEO aiming to set up base in Vietnam, Reuters reports December 10, 2023 Utz Brands to host investor day December 10, 2023 Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term... December 10, 2023 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral... December 10, 2023 Autolus Therapeutics presents clinical data updates at ASH Annual Meeting 2023 December 10, 2023